By combining Biosearch Technologies' targeted genotyping-by-sequencing library preparation methodology (Amp-Seq) with Illumina's proven and highly scalable sequencing technology, the partnership ...

GRAIL faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Click here to ...

After hours: September 27 at 4:45 PM EDT ...

Illumina is estimated to have around 80 ... “Element has taken the first step to democratise sequencing and will continue helping the community uncover the secrets of biology with high-quality ...

The library was used to capture the target regions from eight patients which were then sequenced (single end) on an Illumina GAIIx platform with 35 base read length. Single-end sequencing of control ...

Activist investor, Carl Icahn, put pressure on the company for management changes, leading to deSouza and Illumina’s previous chairman, John Thompson, to step down in the wake of the Grail ...

The Rome Study demonstrated the value of extensive sequencing and discussion of individual cancer cases to offer tailored therapeutic choices.

Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...